<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04659629</url>
  </required_header>
  <id_info>
    <org_study_id>NL201-101</org_study_id>
    <nct_id>NCT04659629</nct_id>
  </id_info>
  <brief_title>NL-201 in Patients With Relapsed or Refractory Cancer</brief_title>
  <official_title>A First-in-Human Phase 1 Study of NL-201 in Patients With Relapsed or Refractory Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neoleukin Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neoleukin Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to understand the safety of NL-201 when given&#xD;
      intravenously as monotherapy in patients with advanced cancer to evaluate tolerability and to&#xD;
      identify a recommended dose and schedule for further testing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will have tests and exams to see if they are eligible for the clinical trial.&#xD;
&#xD;
      If eligible, the patient will receive NL-201 treatment by vein. Tumor response to treatment&#xD;
      will be assessed every 6 weeks for 12 weeks, and every 12 weeks thereafter until disease&#xD;
      progression.&#xD;
&#xD;
      Patients will be able to receive study treatment as long as it is tolerated and there is&#xD;
      evidence of clinical benefit. Safety follow- up will occur within 7 days after the last dose&#xD;
      of NL-201. Patients will then enter long-term follow-up until starting a subsequent therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended phase 2 dose (RP2D) for NL-201</measure>
    <time_frame>Up to Day 33</time_frame>
    <description>Evaluation of tolerability of NL-201 as measured by number of subjects with dose limiting toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended dose schedule for NL-201</measure>
    <time_frame>Up to Day 33</time_frame>
    <description>Evaluation of tolerability of NL-201 as measured by number of subjects with dose limiting toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Up to Day 33</time_frame>
    <description>Rate of adverse events in patients with advanced solid tumors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of treatment-emergent adverse events</measure>
    <time_frame>Up to Day 33</time_frame>
    <description>Rate of adverse event grades in patients with advanced solid tumors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Objective Response according to RECIST version 1.1</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Based on Investigator assessment of radiographic imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) according to RECIST version 1.1</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Based on Investigator assessment of radiographic imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) according to RECIST version 1.1</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Based on Investigator assessment of radiographic imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) according to RECIST version 1.1</measure>
    <time_frame>Upto 36 months</time_frame>
    <description>Based on Investigator assessment of radiographic imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile of NL-201 by half-life (t1/2)</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Prespecified timepoints in serum before and after dosing with NL-201.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile of NL-201 by area under the plasma concentration time curve (AUC)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Prespecified timepoints in serum before and after dosing with NL-201.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile of NL-201 by maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Prespecified timepoints in serum before and after dosing with NL-201.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile of NL-201 by volume of distribution (Vd)</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Prespecified timepoints in serum before and after dosing with NL-201.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of NL-201</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Anti-drug antibodies in serum during and after treatment with NL-201</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Flow cytometry analysis of immune cells in blood</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Based on appropriate assay</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum measurements of inflammatory cytokine levels</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Based on appropriate assay</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of immune characteristics of the tumor microenvironment</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Based on appropriate assay</description>
  </other_outcome>
  <other_outcome>
    <measure>Estimate additional measures of anti-tumor activity of NL- 201 per iRECIST criteria</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Based on Investigator assessment of imaging</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Part 1: NL-201 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NL-201 given by intravenous administration testing ascending doses and two different schedules.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: NL201 Expansion Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NL-201 given by intravenous administration in indication specific cohorts at a dose and schedule determined in Part 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NL-201</intervention_name>
    <description>NL-201 is a de novo protein therapeutic.</description>
    <arm_group_label>Part 1: NL-201 Dose Escalation</arm_group_label>
    <arm_group_label>Part 2: NL201 Expansion Cohorts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with measurable disease&#xD;
&#xD;
          -  Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  At least 6 weeks from any prior nitrosurea or mitomycin C therapy; at least 4 weeks&#xD;
             from any other prior chemotherapy or checkpoint inhibitor; at least 2 weeks from any&#xD;
             kinase inhibitor&#xD;
&#xD;
          -  Patients with relapsed or refractory advanced solid tumor, other than prostate cancer,&#xD;
             who have progressed, not tolerated or are ineligible for all approved lines of therapy&#xD;
&#xD;
          -  Part 2 Only: Patients with kidney and skin cancer who have failed at least 1 line of&#xD;
             systemic therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prostate Cancer&#xD;
&#xD;
          -  Any serious medical condition or laboratory abnormality or psychiatric condition or&#xD;
             any other significant or unstable concurrent medical illness (in the opinion of the&#xD;
             Investigator) would preclude protocol adherence or would make the safety of the study&#xD;
             drug difficult to assess&#xD;
&#xD;
          -  Known or suspected SARS-CoV-2 infection, unless patient tests negative for SARS-CoV-2&#xD;
             within the Screening period&#xD;
&#xD;
          -  History of solid organ transplant or bone marrow transplant&#xD;
&#xD;
          -  Prior CAR-T or allogeneic cellular therapy&#xD;
&#xD;
          -  Prior IL-2-based cancer therapy&#xD;
&#xD;
          -  Ongoing systemic immunosuppressive therapy&#xD;
&#xD;
          -  Concurrent therapy with any other investigational agent, vaccine, or device.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Umut Ulge, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Neoleukin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Lessig</last_name>
    <phone>800-718-4951</phone>
    <email>clinicaltrials@neoleukin.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale/ Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Cassandra Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Winston Tan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Brian Costello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parth Patel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center Oncology and Hematology Care Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Sutliffe</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT- MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Nguyen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Shaw</last_name>
    </contact>
    <investigator>
      <last_name>Evan Hall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Melanoma Institute Australia</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Smith</last_name>
    </contact>
    <investigator>
      <last_name>Georgianna Long, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincents Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Kent</last_name>
    </contact>
    <investigator>
      <last_name>Anthony Joshua, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Olivia Newton-John Cancer Wellness &amp; Research Centre</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Healy</last_name>
    </contact>
    <investigator>
      <last_name>Andrew Weickhardt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UHN - Princess Margaret Cancer Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Zantinge</last_name>
    </contact>
    <investigator>
      <last_name>Aaron Hansen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>NL-201</keyword>
  <keyword>NL201-101</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Cytokine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

